Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (545)	2/11/1999 10:49:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 1073

Jim, Nice article. It highlights the disparity that exists between insider sentiment which is positive and unimpressive price action of the shares. Take IMCL for example, given the confidence of insiders and the apparently stellar results of C225 in Head and Neck trials, why is the stock languishing well below 52 wk high of $14? I don't subscribe to efficient market hypothesis strong form, but the information available leads me to conclude higher stock price. My only answer is that I must have missed something. Either there is a competing drug nearby or C225 isn't all that it's built up to be. I can't find evidence to support either. Holding long, Jackson